Photodynamic effect of light-harvesting, long-lived triplet excited state Ruthenium(II)-polyimine-coumarin complexes: DNA binding, photocleavage and anticancer studies

Coumarin-modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells

Among ruthenium complexes studied as anticancer metallodrugs, NKP-1339, NAMI-A, RM175, and RAPTA-C have already entered clinical trials due to their potent antitumor activity demonstrated in preclinical studies and reduced toxicity in comparison with platinum drugs. Considering the advantages of ruthenium-based anticancer drugs and the cytostatic activity of organometallic complexes with triazole- and coumarin-derived ligands, we set out to synthesize Ru(II) complexes of coumarin-1,2,3,-triazole hybrids (L) with the general formula [Ru(L)(p-cymene)(Cl)]ClO4. The molecular structure of the complex [Ru(2a)(p-cymene)(Cl)]ClO4 (2aRu) was determined by single-crystal X-ray diffraction, which confirmed the coordination of the ligand to the central ruthenium(II) cation by bidentate mode of coordination. Coordination with Ru(II) resulted in the enhancement of cytostatic activity in HepG2 hepatocellular carcinoma cells and PANC-1 pancreatic cancer cells. Coumarin derivative 2a positively regulated the expression and activity of c-Myc and NPM1 in RKO colon carcinoma cells, while the Ru(II) half-sandwich complex 2cRu induced downregulation of AKT and ERK signaling in PANC-1 cells concomitant with reduced intracellular levels of reactive oxygen species. Altogether, our findings indicated that coumarin-modified half-sandwich Ru(II) complexes held potential as anticancer agents against gastrointestinal malignancies.

Photosensitizers Based on Bichromophoric Dyads Combining Ru(II)-Polypyridyl Complexes and Dissymmetric Perylene Monoimide Derivatives: The Nontrivial Role of Ligand Substitution

The covalent modification of Ru(II) polypyridyl complexes (RPCs) with organic chromophores is a powerful strategy to obtain metal-based photosensitizer agents (PSs) with improved performance for application in photodynamic therapy (PDT). In this respect, perylene-imides are of particular interest due to their rich chemical-physical repertoire, and it is therefore quite surprising that their combination with RPCs has been poorly considered so far. Herein, we report on the photophysical behavior of two newly synthesized RPCs bearing a perylene monoimide appendant (PMI-Ad). Differently from the majority of RPCs-perylene-imides dyads, these chromophores are dissymmetric and are tethered to the metal centers through a single C-C bond in the 3- or 5-position of 1,10-phenanthroline (Ru-3PMI-Ad and Ru-5PMI-Ad). Both compounds show excellent singlet oxygen photosensitizing activity, with quantum yields reaching >90% in the case of Ru-3PMI-Ad. A combined spectroscopic and theoretical analysis, also involving transient absorption and luminescence lifetime measurements, demonstrates that both compounds undergo intersystem crossing on a very fast time scale (tens of picoseconds) and with high efficiency. Our results further demonstrate that the increased electron delocalization between the metal center and the PMI-Ad chromophore observed for Ru-3PMI-Ad additionally contributes to increase the singlet oxygen quantum yields by prolonging the lifetime of the triplet state.

Synthesis and Theoretical and Photophysical Study on a Series of Neutral Ruthenium(II) Complexes with Donor-Metal-Accepter Configuration

In order to construct a new type of ruthenium(II) terpyridine complexes with activated triplet metal-centered (³MC) states, as well as stabilized triplet metal-to-ligand charge transfer (³MLCT) states, conducive to fine emissive performances, Ru-1, Ru-2, Ru-3, and Ru-4 were synthesized. Compared with the [Ru(terpyridine)₂]²⁺ prototype (0.25 ns), this series of ruthenium(II) terpyridine complexes exhibit lengthened excited state lifetime (43.3 ns for Ru-1, 52.7 ns for Ru-2, 43.6 ns for Ru-3, and 53.4 ns for Ru-4). Interfragment charge transfer analysis illustrates the electron transfer direction of the four complexes, manifesting their intramolecular charge transfer characteristic. When excited, their lowest-lying triplet states are assigned as ³MLCT based on spin-density surface distribution. The singlet excited states and ³MLCT states were thoroughly studied by UV-visual absorption and nanosecond time-resolved transient absorption spectra, respectively. Photoluminescence spectra revealed their weak broadband near-infrared emission at room temperature and red phosphorescence at 77 K. The low molecular weight and the good thermal stability make Ru-1 and Ru-2 suitable for vaporization coating, while the fine solubility in common organic solvents makes Ru-3 and Ru-4 suitable for solution processing. Furthermore, the intrinsic electroneutrality and favorable energy levels endow them with new potential to be applied in the optoelectronic field.

Cytotoxicity evaluation and DNA interaction of RuII-bipy complexes containing coumarin-based ligands

Although there are various treatment options for cancer, this disease still has caused an increasing number of deaths, demanding more efficient, selective and less harmful drugs. Several classes of ruthenium compounds have been investigated as metallodrugs for cancer, mainly after the entry of imidazolH [trans-RuCl4-(DMSO-S)(imidazole)] (NAMI-A) and indazolH [trans-RuCl4-(Indazol)2] (KP1019) in clinical trials. In this sense, RuII complexes with general formula [Ru(L1-3)(bipy)2]PF6 (1-3) (L1 = ethyl 3-(6-methyl-2-oxo-2H-chromen-3-yl)-3-oxopropanoate, L2 = ethyl 3-(7-(diethylamino)-2-oxo-2H-chromen-3-yl)-3-oxopropanoate, L3 = ethyl 3-(8-methoxy-2-oxo-2H-chromen-3-yl)-3-oxopropanoate and bipy = bipyridine) have been synthesized. The crystal structure of 2 revealed that the RuII atom lies on a distorted octahedral geometry with the deprotonated ligand (L2-) coordinated through β-ketoester group oxygen atoms. In vitro cytotoxic activity of the compounds was evaluated against 4T1 (murine mammary carcinoma) and B16-F10 (murine metastatic melanoma) tumor cells, and the non-tumor cell line BHK-21 (baby hamster kidney). Coordination with RuII resulted in expressive enhancement of cytotoxic activity. The precursors were inactive below 100 μM and the final RuII complexes (1-3) showed IC50 ranging from 2.0 to 12.8 μM; 2 being the most potent compound. DNA interaction studies revealed a greater capacity of the complexes to interact with DNA than the ligands, where, 2 exhibited the highest Kb constant of 2.2 × 104 M-1. Fluorescence investigation demonstrated that 1-3 are capable of quenching the fluorescence emission of the EtdBr-DNA complex up to 40%. Molecular docking showed that the interaction of 1-3 between the DNA base pairs from the coumarin portion was with scores of 67.28, 68.62 and 64.88, respectively, and 75.45 for ellipticine, suggesting an intercalative mode of binding. Our findings show that the RuII complexes are eligible for continuing to be investigated as potential antitumor compounds.

Microwave-assisted synthesis of ruthenium(ii) complexes containing levofloxacin-induced G2/M phase arrest by triggering DNA damage

Ru(ii) complexes have attracted increasing attention as promising antitumor agents for their relatively low toxicity, high affinity to DNA molecules, and correlation with multiple targets. Meanwhile, quinolones are synthetic antibacterial agents widely used in the clinical practice. In this paper, two novel Ru(ii) complexes coordinated by levofloxacin (LOFLX), [Ru(bpy)₂(LOFLX)]·2ClO₄ (1), and [Ru(dmbpy)₂(LOFLX)]·2ClO₄ (2) (bpy = 2,2′-bipyridine, dmbpy = 4,4′-dimethyl-2,2′-bipyridine) were synthesized with high efficiency under microwave irradiation and characterized by ESI-MS, ¹H NMR, and ¹³C NMR. The binding behavior of these complexes with double-strand calf thymus DNA(CT-DNA) was investigated using spectroscopy, molecular docking, and density functional theory calculations. Results showed that 2 exhibited higher binding affinity than 1 and LOFLX. Further studies showed that 2 could induce the G2/M phase arrest of A549 cells via DNA damage. In summary, these results indicated that 2 could be developed as a potential anticancer agent in treatment of lung cancer through the induction of cell cycle arrest at G2/M phase by triggering DNA damage.

This study showed that levofloxacin-based ruthenium(ii) complex 2 effectively inhibited the growth of A549 cells by inducing G2/M phase arrest through triggering DNA damage.

Individual control of singlet lifetime and triplet yield in halogen-substituted coumarin derivatives

The photophysical properties of three 3-diethylphosphonocoumarin derivatives are studied by transient absorption spectroscopy and DFT calculations. The measured lifetime of the first excited singlet state changes upon halogen substitution at the 6-position from 40 ps for the unsubstituted compound to 100 ps for Cl and 24 ps for Br. This observation is in clear contradiction with the estimated singlet–triplet quantum yield, which increases with atomic weight of the substituted atom and is usually referred as a heavy-atom effect. The DFT calculations give evidence that the main reason for this behavior is the different composition of the HOMO, while the LUMO is similar for all three compounds. The optical excitation leads to intramolecular charge transfer from the halogen lone pairs to the π* molecular orbital and thus to a significant change in the molecular dipole moment. Hence, the latter phenomenon in combination with the heavy-atom effect enables an independent control of singlet lifetime and singlet–triplet quantum yield in the studied 3-diethylphosphonocoumarin derivatives.

The photophysical properties of three 3-diethylphosphonocoumarin derivatives are studied by transient absorption spectroscopy and DFT calculations.

Long-lived MLCT states for Ru(ii) complexes of ferrocene-appended 2,2'-bipyridines

In this study, we present two ruthenium(ii) diimine complexes appended with ferrocene which show metal to ligand charge transfer 3MLCT emission lifetimes around 630 ns. We also present a similar complex with two ferrocene units which has decreased emission. These complexes have been studied by electrochemical, electronic absorption, and Raman, resonance Raman and transient resonance Raman means, coupled with density functional theoretical approaches. For these systems, the optical spectra are dominated by a low energy ruthenium(ii) MLCT transition; which can be modulated by the presence of pendant ferrocene units and the extent of conjugation of the ferrocenyl bipyridine backbone. Tuning of the lowest energy transition in terms of intensity (4 to 18 × 10-3 M-1 cm-1) and energy (535 to 563 nm) was achieved by these means.

Microwave-Assisted Synthesis, Characterisation, and DNA-Binding Properties of RuII Complexes Coordinated by Norfloxacin as Potential Tumour Inhibitors

Three novel norfloxacin-based ruthenium(ii) complexes, [Ru(bpy)2(NFLX)]Cl·2H2O (1), [Ru(phen)2(NFLX)]Cl·2H2O (2), and [Ru(dmbpy)2(NFLX)]Cl·2H2O (3) (bpy=2,2′-bipyridine, phen=1,10-phenanthroline, dmbpy=4,4′-dimethyl-2,2′-bipyridine, and NFLX=norfloxacin), were synthesised and characterised with electrospray ionisation mass spectrometry and 1H and 13C NMR spectroscopy. The antitumour properties were evaluated by MTT assay, and the data revealed that 2 can inhibit the growth of human lung adenocarcinoma A549 efficiently. Furthermore, the DNA-binding behaviours of these complexes were investigated by a multiple spectroscopy assay and viscosity study. The results indicated that these complexes interact with calf thymus DNA through electrostatic interactions with a strong binding affinity in the order 2>3>1. Therefore, these results suggested that 2 might be a suitable anticancer agent due to its excellent DNA-binding abilities.

The effect of low- and high-penetration light on localized cancer therapy

The design of a delivery system allowing targeted and controlled drug release has been considered one of the main strategies used to provide individualized cancer therapy, to improve survival statistics, and to enhance quality-of-life. External stimuli including low- and high-penetration light have been shown to have the ability to turn drug delivery on and off in a non-invasive remotely-controlled fashion. The success of this approach has been closely related to the development of a variety of drug delivery systems - from photosensitive liposomes to gold nanocages - and relies on multiple mechanisms of drug release activation. In this review, we make reference to the two extremes of the light spectrum and their potential as triggers for the delivery of antitumor drugs, along with the most recent achievements in preclinical trials and the challenges to an efficient translation of this technology to the clinical setting.

Synthesis and photophysical properties of ruthenium(ii) polyimine complexes decorated with flavin

Phosphorescent emission from a flavin localized triplet excited state (³IL) is observed for the first time in a flavin decorated tris(dipyridine) Ru(ii) complex with strong visible light absorption.